Xintela (XINT) announces that the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers has been completed with the last follow-up visit for the last ...

Speedy inclusion of the first 10 dogs, out of a total of 51, within one month of study startTop-line data expected by Q4 2026Blockbuster potential as the first disease-modifying therapy to halt bone l ...

Medivir AB (FRA:MVR0) showcases significant pipeline progress and a robust financial position despite facing developmental challenges.

A new study shows early specialization boosts short-term success but limits long-term excellence. Range, not early focus, ...

As marijuana use among teens has grown in the past decade, researchers have been trying to better understand the health risks ...

PRESS RELEASEAB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF ...

The history: The bakery sits on Central Avenue, the focal point of Black Los Angeles between the 1930s and 1960s. As ...

Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the ...

Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) ...

The recent activities of JI and the NCP indicate that the alliance will continue. As the opposition in the 13th Parliament, ...

Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today ...

In a sign of how toxic the briefing war has become around Sir Keir Starmer’s pick to head up the civil service, even office ...